Clincierge
Clincierge is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Sponsor Apellis Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available8 trial-level findings · Read insights
- The study enrolled 124 participants at 122 sites across 18 countries; enrollment was highest in the United States (31), Brazil (19), and Italy (17).
- Recruitment started on 30 May 2022, and the global end-of-trial date was 14 January 2025.
- A protocol amendment changed planned enrollment from 90 to 80–100 participants.
- An amendment removed eGFR from the primary efficacy endpoint and moved primary and key secondary efficacy assessments from Week 52 to Week 26.
- An amendment increased the screening period from 8 to 10 weeks and total study participation duration to 70 weeks.
- Eligibility and dosing amendments increased the minimum body weight to 30 kg and added weight-based dosing regimens for adolescents.
- The minimum planned adolescent enrollment was increased from 8 to 10 participants.
- Follow-up for participants who did not continue pegcetacoplan was shortened from 24 to 8 weeks.
These findings describe the trial, not the service provider’s performance or responsibility.
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALE)
Sponsor Apellis Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003‑P) in Participants with Tuberous Sclerosis Complex (1 Month to < 2 Years of Age), Dravet Syndrome (1 Year to < 2 Years of Age), or Lennox-Gastaut Syndrome (1 Year to < 2 Years of Age) who Experience Inadequately‑controlled Seizures
Sponsor Gw Research Limited
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Clincierge?
The 2026-10-09 snapshot links Clincierge to 5 distinct CTIS trials. Recorded services include Patient reimbursement, Patient Reimbursement, Patient's travels arrangements and reimbursement, Patients’ Travels arrangements and reimbursement. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Clincierge?
The most frequently recorded therapeutic areas are Haematological Malignancies, Nephrology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Clincierge conducted?
The linked trials record locations in 17 countries, including Germany, Italy, Austria, Spain, France. These are trial locations, not confirmed office locations or countries where Clincierge delivered services.
What can this page tell me about Clincierge's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Clincierge. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Clincierge